News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Vaccines
New insights into HIV vaccine will improve drug development

Four years ago, a potential HIV vaccine showed promise against the virus that causes AIDS, but it fell short of providing the broad protection necessary to stem the spread of disease. Now researchers -- led by Duke Medicine -- have gained additional insights into the workings of the vaccine that help explain why it benefited a third of recipients and left others vulnerable.

Published
11 January 2013
From
Science Daily
Side-effects
FDA clears Salix anti-diarrhoeal for HIV patients

The US Food and Drug Administration has approved the first anti-diarrhoeal drug specifically for people with HIV, Salix Pharmaceuticals Ltd.'s Fulyzaq. The drug, also known as crofelemer, is meant to relieve symptoms of noninfectious diarrhoea in people with HIV on antiretroviral therapy. Fulyzaq is derived from the red sap of the Croton lechleri plant and is the second botanical prescription drug approved by the FDA. However, although crofelemer produced a 55% reduction in watery diarrhoea in people with HIV on ART who chronically suffered from it, this only means that 17.6% of patients improved during the study period rather than 8% given a placebo.

Published
02 January 2013
From
MarketWatch
New and experimental HIV treatments
ViiV Files Regulatory Applications for New Integrase Inhibitor Dolutegravir

ViiV Healthcare announced it has filed regulatory applications for the company’s investigational HIV integrase inhibitor dolutegravir.

Published
19 December 2012
From
AIDSMeds
New and experimental HIV treatments
ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada

ViiV Healthcare today announced the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572) for the treatment of HIV infection in adults and adolescents.

Published
18 December 2012
From
ViiV press release
Vaccines
Major Breakthrough in HIV Research: Swiss Vaccine Research Institute

A study published today online in The Journal of Experimental Medicine has identified the population of CD4 T cells serving as the major reservoir for HIV infected cells and as the primary cell site for HIV replication and production in infected patients. The identification of the major HIV CD4 T cell reservoir will be instrumental in developing therapeutic strategies to selectively target HIV infected cells.

Published
18 December 2012
From
Business Wire
HIV treatment in children
DNDi is awarded USD 17.3 million from UNITAID to spur development and delivery of child-adapted ARVs

The Drugs for Neglected Diseases initiative welcomes the announcement by UNITAID to grant up to USD 17.3 million to the organization for its pediatric HIV program.

Published
12 December 2012
From
Eurekalert Inf Dis
New and experimental HIV treatments
Six Promising HIV Drugs in the Pipeline

What new HIV medications do we have to look forward to over the next few years? How will these newer drugs improve upon the older ones? To shed some light on these questions, Roy Gulick, M.D., provided an overview at ID Week 2012 of drugs in development.

Published
11 December 2012
From
The Body Pro
New and experimental HIV treatments
FDA approves prescribing information update for EDURANT® (rilpivirine)

On December 7, 2012, FDA approved changes to the Edurant (rilpivirine) package insert. The major changes include restricting the indication to treatment-naïve adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL, updating the package insert with the 96 week results from the Phase 3 trials and adding a new Warning and Precaution for hepatotoxicity.

Published
11 December 2012
From
Janssen press release
New and experimental HIV treatments
Crucial step in AIDS virus maturation simulated for first time

Bioinformaticians in Spain have used molecular simulation techniques to explain a specific step in the maturation of the HIV virions, i.e., how newly formed inert virus particles become infectious, which is essential in understanding how the virus replicates. These results could be crucial to the design of future antiretrovirals.

Published
05 December 2012
From
Science Daily
Vaccines
THERAVECTYS is granted authorization from the French and Belgian regulatory agencies to launch a Phase III clinical trial for its anti-HIV therapeutic vaccine candidate

The world’s first use of lentiviral vector technology in the vaccine field .

Published
04 December 2012
From
EATG
← Prev12345...66Next →

Filter by country